- Design
- Systematic review of 21 preclinical and clinical studies
- Population
- 8,910 patients with rheumatoid arthritis treated with TNF inhibitors in 18 clinical studies
- Primary outcome
- Disease activity and remission by rheumatoid factor level
- Effect
- Outcomes with Fc-free TNF inhibitors similar or slightly better in high-RF than low-RF patients (no pooled estimate)
A systematic review in Annals of the Rheumatic Diseases (5 October) examined whether high rheumatoid factor (RF) reduces the effect of TNF inhibitors in rheumatoid arthritis. The proposed mechanism is that RF binds the Fc portion of IgG-based biologics, forming immune complexes that are cleared, lowering drug levels. Twenty-one studies were included, 18 reporting clinical outcomes in 8,910 patients.
The authors report that disease activity and remission outcomes in patients with high RF treated with an Fc-free TNF inhibitor were similar to, or slightly better than, those with low RF. The abstract does not give pooled effect sizes or a direct comparison with Fc-containing agents.
The idea is biologically plausible and could inform biologic choice in strongly RF-positive patients with poor response. But the evidence summarised is heterogeneous and indirect, and no randomised trial has compared Fc-free and Fc-containing TNF inhibitors by RF level. It is not yet a basis for choosing one agent over another.
- Record RF titre as well as positivity before starting a biologic in rheumatoid arthritis.
- In a patient with high RF and inadequate response to a TNF inhibitor, consider drug level and antibody testing where available.
- Do not switch TNF inhibitors on the basis of RF level alone without evidence of poor response.
- Follow current guideline sequencing for biologics; this review does not change it.
Why it matters
It raises a testable reason why some RF-strong patients respond poorly to standard TNF inhibitors.
Don't overread it
This review gives no pooled effect estimates and no head-to-head randomised comparison of Fc-free and Fc-containing agents.
The statistics, in plain English
A systematic review without meta-analysis describes studies rather than combining them, so the direction of results is less certain than a pooled estimate would be.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free